AstraZeneca's Seroquel XR Ruled Valid And Infringed

Law360, New York (March 30, 2012, 2:01 PM EDT) -- A New Jersey federal judge on Thursday found that four generics makers infringed an AstraZeneca PLC patent on the anti-psychotic Seroquel XR, effectively clearing the path for AstraZeneca to sell the blockbuster drug without generic competition for the next five years.

The ruling resolves suits brought by AstraZeneca against Mylan Inc., Torrent Pharmaceuticals Ltd., Anchen Pharmaceuticals Inc. and Osmotica Pharmaceutical Corp., each of which had filed abbreviated new drug applications with the U.S. Food and Drug Administration to make generic versions of the extended release Seroquel...
To view the full article, register now.